Zydus Lifesciences Advances Desidustat into Phase III Sickle Cell Trial in Partnership with ICMR
核心洞察
Zydus Lifesciences has received regulatory approval to conduct a Phase III clinical trial of oral desidustat in 164 patients with sickle cell disease (搜索), in collaboration with the Indian Council of Medical Research (ICMR).
The 203-day study follows a successful Phase II trial in which the 150 mg dose demonstrated promising hemoglobin improvement with minimal adverse events.
Desidustat, a hypoxia-inducible factor (搜索)-prolyl hydroxylase inhibitor (HIF-PHI), stimulates endogenous erythropoietin production and iron utilization, offering a novel oral mechanism for treating anemia (搜索) in sickle cell disease (搜索).
Zydus Lifesciences has received regulatory clearance to initiate a Phase III clinical trial evaluating desidustat, an oral hypoxia-inducible factor (搜索)-prolyl hydroxylase inhibitor (HIF-PHI), in patients with sickle cell disease (搜索). The 203-day study will be conducted in collaboration with the Indian Council of Medical Research (ICMR) and will enroll 164 patients diagnosed with anemia (搜索) associated with sickle cell disease.
The trial marks a significant advancement for a disease that imposes a substantial public health burden in India. According to National Health Mission estimates, approximately 50,000 children are born with sickle cell anemia (搜索) annually in the country, and nearly 20 million people live with the condition. Existing treatments such as hydroxyurea and blood transfusions carry inconsistent effectiveness and associated risks that remain significant clinical challenges.
Mechanism of Action and Clinical Rationale
Desidustat works by stabilizing hypoxia-inducible factors (HIFs), proteins that orchestrate the body's natural response to low oxygen levels. By inhibiting prolyl hydroxylase enzymes that normally degrade HIFs, desidustat preserves these transcription factors, thereby stimulating endogenous production of erythropoietin (EPO) — the hormone essential for red blood cell production. This mechanism mimics the body's physiological response to hypoxia, boosting both natural EPO levels and iron utilization without requiring injectable therapies.
Phase II Results and Regulatory Context
The Phase III trial builds on positive data from a multi-center Phase II study, in which the 150 mg dose of desidustat demonstrated "promising improvement in hemoglobin (Hb) levels, with only minimal adverse events," according to Zydus.
"We have successfully completed the Phase II study of desidustat in Sickle Cell in collaboration with Zydus and this truly marks a significant leap forward for patients who have limited options beyond hydroxyurea," said Dr. Rajiv Bahl, Secretary and Director General of ICMR.
Desidustat is already approved in India for treating anemia (搜索) in patients with chronic kidney disease (搜索) (CKD), including those on dialysis. Earlier this year, the National Medical Products Administration (NMPA) of China also approved the drug for the same indication. Additionally, desidustat holds Orphan Drug Designation from the US FDA for sickle cell disease (搜索), which provides benefits including tax credits, fee exemptions, and potential marketing exclusivity.
Strategic Significance
"Sickle cell disease (搜索) severely impacts the lives of millions of people. Desidustat, discovered and developed at the Zydus Research Centre, reflects our commitment to advancing novel innovations and improving the quality of life for patients," said Sharvil Patel, MD, Zydus Lifesciences.
The clinical progression of desidustat underscores Zydus's transition from a generics producer to a research-driven specialty pharmaceutical company. The public-private partnership with ICMR aligns clinical development with public healthcare mandates while reducing trial execution risks. Positive data from the Phase III trial could open pathways for international out-licensing deals and clinical development in Western markets, where US FDA Orphan Drug benefits provide additional commercial incentives.
Sickle cell disease (搜索) is an inherited genetic blood disorder that leads to severe anemia (搜索), pain crises, and organ damage, disproportionately affecting populations in India's tribal belts. Standard treatments such as hydroxyurea are constrained by side effects, while blood transfusions present logistical challenges and carry risks of iron overload. Desidustat, as an oral HIF-PHI, represents a potentially transformative approach to managing anemia in this underserved patient population.